Short answer
Cencora (COR) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $78.4B (up 3.8% year over year) with net income of $1.6B.
Q1 2026 key financials · XBRL
- Revenue
- $78.4B
- +3.8% YoY · −8.8% QoQ
- Net income
- $1.6B
- +128.6% YoY · +193.3% QoQ
- Operating margin
- 1.5%
- Gross margin
- 4.6%
- EPS (diluted)
- $8.40
- +128.3% YoY · +192.7% QoQ
Source: XBRL data from the Cencora (COR) Q1 2026 10-Q on SEC EDGAR. USD.
Cencora Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $78.4B, up 3.8% YoY from $75.5B
- U.S. Healthcare Solutions revenue $68.8B, up 2.9%; GLP-1 sales $1.9B, up 23.0%
- Operating income $1.14B, up 10.3%; effective tax rate 22.0% vs 22.7%
- International Healthcare Solutions strongest segment, revenue up 13.0% to $7.6B
- Operations used $1.0B cash versus $0.6B generated YoY; OneOncology acquisition consideration $7.4B financed with debt and cash
Risk Factors
- No risk factors provided; excerpt covers issuer share repurchases only
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cencora quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.